Efficacy of erythroid‐stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group

Efficacy of erythroid‐stimulating agent and luspatercept in VEXAS syndrome: A multicenter retrospective study by the FRENVEX group

Saved in:

Bibliographic Details
Main Authors:	Maël Heiblig, Vincent Jachiet, Jérôme Hadjadj, Lin Pierre Zhao, Thibault Comont, Hervé Lobbes, Valentin Lacombe, Anne Blandine Boutin, Joris Galland, Benjamin Terrier, Sophie Georgin‐Lavialle, Pierre Fenaux, Arsène Mekinian, the FRENVEX Group
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	HemaSphere
Online Access:	https://doi.org/10.1002/hem3.70156
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Very long-term remission with azacitidine in VEXAS syndrome
by: Lin-Pierre Zhao, et al.
Published: (2025-01-01)

A Clinicopathological Description of Kidney Features in VEXAS Syndrome
by: Martin Mathurin, et al.
Published: (2025-01-01)

Think VEXAS: a case report of Vexas syndrome
by: T. Najdi, et al.
Published: (2024-11-01)

VEXAS Syndrome: An Overlooked Threat
by: Serdal Uğurlu, et al.
Published: (2025-05-01)

Understanding Myelodysplasia and Inflammation Through the Lense of VEXAS Syndrome: A Review
by: Louis Wolff, et al.
Published: (2024-11-01)

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
by: Xiangke Xin, et al.
Published: (2025-02-01)

VALUE OF EARLY LUSPATERCEPT USE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES
by: D Valcárcel, et al.
Published: (2024-10-01)

VEXAS Syndrome and Alzheimer’s Disease—Are There Connections?
by: Aleksandra Sowa, et al.
Published: (2025-05-01)

Digital Track Map for the VEXA expert system
by: Adam Hlubuček
Published: (2022-05-01)

Is immunotherapy safe and effective in patients with VEXAS syndrome?
by: Chiara Marvisi, et al.
Published: (2025-07-01)

Case report: VEXAS syndrome and literature review
by: Can Jones, et al.
Published: (2024-11-01)

VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia
by: Janne Austestad, et al.
Published: (2023-01-01)

Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?
by: Khaled M. Musallam, et al.
Published: (2025-07-01)

VEXAS syndrome: on the threshold of changing perceptions of known diseases
by: B. D. Chaltsev, et al.
Published: (2023-12-01)

Macrocytic Anemia: A Presenting Feature of VEXAS Syndrome
by: Indira Acharya, et al.
Published: (2024-06-01)

VEXAS syndrome: a Swiss national retrospective cohort study
by: Louis Wolff, et al.
Published: (2024-03-01)

VEXAS: A review of current understandings and emerging treatment strategies
by: Robert Holden, et al.
Published: (2025-07-01)

Luspatercept in β‐thalassemia: Who and when. Strengths and weaknesses points of a real‐world evidence
by: Lorenza Torti, et al.
Published: (2024-12-01)

SUCCESSFUL REDUCTION OF TRANSFUSION DEPENDENCE WITH LUSPATERCEPT IN A PATIENT WITH THALASSEMIA MAJOR: A CASE REPORT
by: Gökhan Demirci, et al.
Published: (2024-12-01)

Ferroportin and Erythroid Cells: An Update
by: Luciano Cianetti, et al.
Published: (2010-01-01)

Promise of Jak Inhibition in the Management of VEXAS, Case Report with Review of the Literature
by: Alnahas Z, et al.
Published: (2025-07-01)

Antitumor properties of nuclear erythroid cells
by: V. A. Kozlov, et al.
Published: (2022-06-01)

PLK1 inhibition impairs erythroid differentiation
by: Peijun Jia, et al.
Published: (2024-12-01)

VEXAS syndrome in a Moroccan patient: the story of a two-year diagnostic lag
by: Abire Allaoui, et al.
Published: (2025-06-01)

Baseline erythropoietin level predicts Luspatercept response in Chinese patients with myelodysplastic syndrome: a propensity score-matched analysis
by: Doudou Chang, et al.
Published: (2025-01-01)

LUSPATERCEPT UTILIZATION PATTERNS IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: FINDINGS FROM A MULTINATIONAL MEDICAL RECORD REVIEW STUDY
by: M Díez-Campelo, et al.
Published: (2024-10-01)

La difficile construction d’une expertise européenne indépendante
by: Jean-Pierre Galland
Published: (2013-03-01)

In depth transcriptomic profiling defines a landscape of dysfunctional immune responses in patients with VEXAS syndrome
by: Hiroki Mizumaki, et al.
Published: (2025-05-01)

How Protein Ubiquitination Can Influence Cytokine Expression—Updated Review on Autoinflammatory VEXAS Syndrome
by: Dominika Majer, et al.
Published: (2024-09-01)

Nuclear RNA sequencing of the mouse erythroid cell transcriptome.
by: Jennifer A Mitchell, et al.
Published: (2012-01-01)

LONG-TERM EFFECTIVENESS AND SAFETY OF LUSPATERCEPT FOR ANEMIA TREATMENT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES: A SYSTEMATIC REVIEW AND META-ANALYSIS
by: DVS Cavalcante, et al.
Published: (2024-10-01)

Unveiling VEXAS Syndrome: When Skin Manifestations and Monoclonal Gammopathy Precede Myeloid‐Lineage Hematologic Abnormality
by: Laura Di Centa, et al.
Published: (2025-06-01)

VEXAS syndrome caused by a UBA1 mutation is complicated by recurrent infections leading to hemophagocytic lymphohistiocytosis
by: Yu Tang, et al.
Published: (2025-09-01)

Murine hematopoietic progenitor cell lines with erythroid and megakaryocyte potential
by: Ruiqiong Wu, et al.
Published: (2025-08-01)

CONDITION OF THE ERYTHROID PART OF BLOOD SYSTEM AT STRESSED ANIMALS WITH HYPOTHYREOSIS
by: D. V. Garmayeva, et al.
Published: (2012-02-01)

Luspatercept for the treatment of lower-risk myelodysplastic syndrome with SF3B1 mutation: a real-world single-center research in China
by: Weiru Liang, et al.
Published: (2025-12-01)

Qualitative and quantitative comparison of the proteome of erythroid cells differentiated from human iPSCs and adult erythroid cells by multiplex TMT labelling and nanoLC-MS/MS.
by: Kongtana Trakarnsanga, et al.
Published: (2014-01-01)

Exploring patient-reported outcomes and morbidity burden of patients with VEXAS syndrome: a scoping reviewResearch in context
by: Fabio Efficace, et al.
Published: (2025-08-01)

Complex somatic mutation landscape in myeloid cells in a patient with VEXAS syndrome: First Brazilian case report
by: Fabíola Reis de Oliveira, et al.
Published: (2025-01-01)

A Case of VEXAS (Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic) Syndrome With Cardiac Involvement
by: Xiaocao Xu, et al.
Published: (2024-05-01)